The David Geffen School of Medicine at UCLA is consistently highly ranked in the U.S. in research dollars and research funding from the NIH. The UCLA Institute of Urologic Oncology has one of the largest and most diverse urologic oncology research programs in the nation.
The UCLA Institute of Urologic Oncology (IUO) is committed to ongoing prostate cancer research in a quest to develop new treatments and cures for all prostate cancer patients, along with a commitment to educate and train the next generation of leading physician-scientists. The UCLA IUO is conducting pioneering basic (bench) research, cutting-edge translational research (bench to bedside) and offering newly-designed clinical trials for prostate cancer.
A campus-wide effort to focus on prostate cancer led by researchers working within The UCLA Institute of Urologic Oncology, the UCLA SPORE in Prostate Cancer and a broad array of departments across the UCLA campus has led to significant research discoveries and achievements with potential major impact on men with prostate cancer. Examples of these discoveries and achievements include:
The FDA approved Gallium 68 PSMA-11 (68Ga-PSMA-11) for positron emission tomography (PET) imaging of prostate cancer on December 1st, 2020.
The UCLA IUO will continue to apply the diversity of talent on the UCLA campus to the critical and evolving translational challenges in the field of prostate cancer.